Sepsis and cytokines: Current status

British Journal of Anaesthesia

Volumn 77, Issue 1, 1996, Pages 110-117

  Blackwell, T S ^a   Christman, J W ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cells, metabolism; Complications, infection; Infection, systemic inflammatory response syndrome; Protein, cytokines

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 0029944101     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/77.1.110     Document Type: Article

References (72)

1. Aderka D, Le J, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumour necrosis factor production in cultured human monocytes, U937 cells and mice. Journal of Immunology 1989; 143: 3517-3523.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 20: 864-974.
3. Bernard GR. Sepsis trials: intersection of investigation, regulation, funding, and practice. American Journal Respiratory and Critical Care Medicine 1995; 152: 4-10.
4. Borden EC, Chin P. Interleukin-6: a cytokine with potential diagnostic and therapeutic roles. Journal of Laboratory and Clinical Medicine 1994; 123: 824-829.
5. Calandra T, Gerain J, Heumann D, Baumgartner J-D, Glauser MP and the Swiss-Dutch J5 Immunoglobulin Study Group. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. American Journal of Medicine 1991; 91: 23-29.
6. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JWM, Endres S, Lonnemann G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Burke JF, Dinarello CA. Circulating interleukin-1 and tumour necrosis factor in septic shock and experimental endotoxin fever. Journal of Infectious Diseases 1990; 160: 79-84.
7. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Annals of Internal Medicine 1993; 119: 771-778.
8. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HF. Clinical pharmacology of recombinant tumour necrosis factor in patients with advanced cancer. Journal of Clinical Oncology 1987; 5: 1942-1951.
9. Chollet-Martin S, Montravers P, Gibert C, Elbim C, Desmonts JM, Fagon JY, Gougerot-Pocidalo MA. High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infection and Immunity 1993; 61: 4553-4559.
10. Christman JW, Blackwell TS. Paradoxical molecular regulation of soluble cytokine receptors in human sepsis. In: Debets R, ed. Methods in Molecular Biology: Protocols in Human Cytokine Research. Totowa, NJ: The Humana Press, 1996 in press.
11. Creasey AA, Stevens P, Kenney J, Allison AC, Warren K, Catlett R, Hinshaw L, Taylor FB. Endotoxin and cytokine profile in plasma of baboons challenges with lethal and sublethal Escherichia coli. Circulatory Shock 1991; 33: 84-91.
12. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franshimont P, Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Annals of Surgery 1992; 215: 356-362.
13. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. Journal of Infectious Diseases 1995; 171: 229-232.
14. Dinarello CA. The endogenous pyrogens in host defense interactions. Hospital Practice 1989; 24: 111-128.
15. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunology Today 1991; 12: 404-110.
16. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-1652.
17. Emerson TE, Lindsey DC, Jesmok GJ, Duerr ML, Fournel MA. Efficacy of monoclonal antibody against tumour necrosis factor alpha in an endotoxemic baboon model. Circulation Shock 1992; 38: 75-84.
18. Endo S, Inada K, Inoue Y, Kuwata Y, Suzuki M, Yamashita H, Hoshi S, Yoshida M. Two types of septic shock classified by the plasma level of cytokines and endotoxin. Circulatory Shock 1992; 38L 264-274.
19. Ertel W, Scholl FA, Gallati H, Bonaccio M, Schildberg FW, Trentz O. Increased release of soluble tumour necrosis factor receptors into blood during clinical sepsis. Archives of Surgery 1994; 129: 1330-1336.
20. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, Thompson RC, Lowry SF, Moldawer LL. Interleukin 1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. Journal of Clinical Investigation 1992; 89: 1551-1557.
21. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo C, Allison AC, Lowry SF, Cerami A. Antibodies to cachexin/tumour necrosis factor reduces interleukin-1β and interleukin 6 appearance during lethal bacteremia. Journal of Experimental Medicine 1989; 170: 1627-1633.
22. Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts C-J, Wretlind B. Plasma levels of cytokines in primary septic shock in humans : correlation with disease severity. Journal of Infectious Diseases 1995; 172: 296-301.
23. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vanderbeele P, Delvaux A, Fiers W, Goldman M, Velu T. Interleukin-10 reduces the release of tumour necrosis factor and prevents lethality in experimental endotoxemia. Journal of Experimental Medicine 1993; 177: 547-550.
24. Goldie AS, Fearon KC, Ross JA, Barclay GR, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC. Natural cytokine antagonist and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. Journal of the American Medical Association 1995; 274: 172-177.
25. Gomez-Jimenez J, Martin MC, Sauri R, Segura RM, Estgan F, Ruiz JC, Nuvials X, Boveda JL, Peracaula R, Salgado A. Interleukin-10 and the monocytic/macrophage-induced inflammatory response in septic shock. Journal of Infectious Diseases 1995; 711: 472-475.
26. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA. Increased plasma level of interleukin-6 in sepsis. Blood 1989; 74: 1704-1710.
27. Hack CE, Hart M, Strack van Schijndel RJM, Eerenberg AJM, Nuijens JH, Thijs LG, Aarden LA. Interleukin-8 in sepsis: Relation to shock and inflammatory mediators. Infection and Immunity 1992; 60: 2835-2842.
28. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA jr, Cerami A, Shires GT, Lowry SF. Cytokine appearance in human endotoxemia and primate bacteremia. Surgery, Gynecology and Obstetrics 1988; 166: 147-153.
29. Hinshaw LB, Emerson TE, Taylor FB, Chang ACK, Duerr M, Peer GT, Flournoy DJ, White GL, Kosanke SD, Murray CK, Xu R, Passey RB, Fournel MA. Lethal Staphylococcus aureus-induced shock in primates prevention of death with anti-TNF antibody. Journal of Trauma 1992; 33: 568-573.
30. Johnson J, Meyrick B, Jesmok G, Brigham KL. Human recombinant tumour necrosis factor a induction mimics endotoxemia in awake sheep. Journal of Applied Physiology 1989; 66: 1448-1454.
31. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Einer VM, Einer SG, Stricter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801.
32. Kuhns DB, Alvord WG, Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. Journal of Infectious Diseases 1995; 171: 145-152.
33. Libert C, Vink A, Coulie P, Brouchaert P. Evaraerdt B, van Snick J, Fiers W. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. European Journal of Immunology 1992; 22: 2625-2630.
34. Marchant A, Deviere J, Byl B, De Groote D, Vincent JL, Goldman M. Interleukin-10 production during septicaemia. Lancet 1994; 343: 707-708.
35. Marchant A, Bruyns C, Vanderbeele P, Abramowitcz D, Gerard C, Delvauz A, Ghezzi P, Velu T, Goldman M. The protective role of interleukin-10 in endotoxin shock. In: Levin J, Sander JH, van Deventer T, van der Poll AS, eds. Progress in Clinical and Biological Research: Bacterial Endotoxin: Basic Science to Anti-Sepsis Strategies. New York: Wiley-Liss, 1994; 388: 417-423.
36. Martin C, Sauzx P Mege JL, Perrin G, Papazian L, Gouin F. Prognostic value of serum cytokines in septic shock. Intensive Care Medicine 1994; 20: 272-277.
37. Marty C, Misset B, Tamion F, Fitting C, Carlet J, Cavaillon JM. Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin. Critical Care Medicine 1994; 22: 673-679.
38. McAllister SK, Bland LA, Arduino MJ, Wenger PN, Jarvis WR. Patient cytokine response in transfusion-associated sepsis. Infection and Immunity 1994; 62: 2126-2128.
39. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolpe SA, Wilmore DW. Detection of circulating tumour necrosis factor after endotoxin administration. New England Journal of Medicine 1988; 318: 1481-1485.
40. Miller EJ, Cohen AB, Nagao S, Griffith D, Maunder RJ, Martin TR, Weiner-Kronish JP, Sticherling M, Christophers E, Matthay MA. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. American Review of Respiratory Diseases 1992; 146: 427-432.
41. Moscovitz H, Shofer F, Mignott H, Behrman A, Kilpatrick L. Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity. Critical Care Medicine 1994; 22: 1102-1107.
42. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550.
43. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-575.
44. Preiser JC, Schmartz D, van der Linden P, Content J, vanden Bussche P, Buurman W, Sebald W, Dupont E, Pinsky, MR, Vincent JL. Interleukin-6 administration has no acute hemodynamic or hematologic effects in the dog. Cytokine 1991; 3: 1.
45. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. Journal of the American Medical Association 1995; 11: 117-123.
46. Redl H, Schlag G, Ceska M, Davies J, Buurman WA. Interleukin-8 release in baboon septicemia is partially dependent on tumour necrosis factor. Journal of Infectious Diseases 1993; 167: 1464-1466.
47. Rogy MA, Auffenberg T, Espat NJ, Philip R, Remick D, Wollenberg GK, Copeland EM 3rd, Moldawer LL. Human tumour necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuate local inflammatory responses. Journal of Experimental Medicine 1995; 181: 2289-2293.
48. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1 and tumour necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-47.
49. Seckinger P, Dayer JM. Interleukin-1 inhibitors. Annals of the Institute Pasteur/Immunology 1987; 138: 461.
50. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993; 365: 654-657.
51. Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, Shiga T. Tumour necrosis in man : clinical and biological observations. British Journal of Cancer 1987; 56: 803-808.
52. Shalaby MR, Waage A, Aarden L, Espevik T. Endotoxin, tumour necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo. Clinical Immunology and Immunopathology 1989; 53: 488-498.
53. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei III E, Kufe DW. Recombinant human tumour necrosis factor administered as a five-day continuous infusion in cancer patients: Phase I toxicity and effects on lipid metabolism. Journal of Clinical Oncology 1988; 6: 344-350.
54. Sheron N, Bird G, Goka J, Alevander G, Williams R. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clinical and Experimental Immunology 1991; 84: 449-453.
55. Siebenlist U, Franzoso G, Brown K. Structure, regulation, and function of NF-κB. Annual Review of Cell Biology 1994; 10: 405-455.
56. Smith J, Urba W, Steis R, Janik J, Fenton B, Sharfman W, Conlon K, Sznol M, Creekmore S, Wells N, Elwood L, Keller J, Hestdal K, Ewel C, Rossio J, Kopp W, Shimuzut M, Oppenheim J, Longo D. Interleukin-1 alpha: results of a phase I toxicity and immunomodulatory trial. American Society of Clinical Oncology 1990; 9: 717.
57. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumour necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. Journal of Clinical Investigation 1992; 90: 533-536.
58. Stricter RM, Kunkel SL, Bone RC. Role of tumour necrosis factor-alpha in disease states and inflammation. Critical Care Medicine 1993; 21: S447-463.
59. Suffredini AF. Current prospects for the treatment of clinical sepsis. Chest 1994; 22: S12-S18.
60. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. New England Journal of Medicine 1989; 321: 280-287.
61. Sullivan JS, Kilpatrick L, Costarino AT, Lee SC, Harris MC. Correlation of plasma cytokine elevations with mortality rate in children with sepsis. Journal of Pediatrics 1992; 120: 510-515.
62. Swenssen O, Schubert C, Christophers E, Schroder JM. Inflammatory properties of neutrophil-activating protein-1/interleukin 8 (NAP-1/IL-8) in human skin: a light- and electronmicroscopic study. Journal of Investigation Dermatology 1991; 96: 682-689.
63. Tracey KJ, Fong JY, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachetin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330: 662-664.
64. van der Poll T, Buller HR, ten Cate HT. Activation of coagulation after administration to TNF to normal subjects. New England Journal of Medicine 1990; 322: 1622-1627.
65. van der Poll T, Levi M, Hack CE, ten Vate H, van Deventer SJ, Eerenberg AJ, de Groot ER, Jansen J, Gallati H, Buller HR, ten Gate JW, Aarden LA. Elimination of interleukin 6 attenuate coagulation activation in experimental endotoxemia in chimpanzees. Journal of Experimental Medicine 1994; 179: 1253-1259.
66. van Deuren M, van der Ven-Jongekrijg J, Bartelink AKM, van Dalen R, Sauerwein RW, van der Meer JWM. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. Journal of Infectious Diseases 1994; 172: 433-439.
67. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumour necrosis factor soluble receptor circulate during experimental and clinical inflammation and can protect against excessive tumour necrosis factor α in vitro and in vivo. Proceedings of National Academy of Sciences USA 1992; 89: 4845-4849.
68. Van Zee KJ, DeForge LE, Fischer E, Marano MA, Kenney JS, Remick, Lowry SF, Moldawer LL. IL-8 in septic shock, endotoxemia, and after IL-1 administration. Journal of Immunology 1991; 146: 3478-3482.
69. Van Zee KJ, Fischer E, Hawes AS, Hebert CA, Terrell TG, Baker JB, Lowry SF, Moldawer LL. Effects of intravenous IL-8 administration in nonhuman primates. Journal of Immunology 1992; 148: 1746-1752.
70. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355-359.
71. Wheeler AP, Jesmok G, Brigham KL. Tumour necrosis factor's effect on lung mechanics, gas exchange and airway reactivity in sheep. Journal of Applied Physiology 1990; 68: 2542-2549.
72. Xing Z, Braciak T, Jordana M, Croitoru K, Graham FL, Gauldle J. Adenovirus-mediated cytokine gene transfer at tissue sites. Overexpression of IL-6 induces lymphocyte hyperplasia in the lung. Journal of Immunology 1994; 153: 4059-4069.